EMD Serono Enters into Research Agreement with Pfizer and Broad Institute

  EMD Serono Enters into Research Agreement with Pfizer and Broad Institute

- Agreement aims to identify biomarkers relevant to future therapies in the
area of Systemic Lupus Erythematosus and Lupus Nephritis

PR Newswire

ROCKLAND, Mass., April 1, 2014

ROCKLAND, Mass., April 1, 2014 /PRNewswire/ -- EMD Serono, a subsidiary of
Merck KGaA, Darmstadt, Germany, today announced they have signed a research
agreement with Pfizer Inc. and the Broad Institute in Cambridge,
Massachusetts, U.S. The collaboration is focused on the genomic profiling of
Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients. The
research project will be jointly funded by EMD Serono and Pfizer.

EMD Serono logo

SLE is a systemic autoimmune disease, and can cause LN, an inflammation of the
kidney. In SLE patients, in addition to the kidney, other tissues and organs
can be affected, including the skin, the nervous system, or joints.

As part of the collaboration, the Broad Institute will investigate clinical
samples obtained from SLE and LN patients, applying biochemical and
next-generation sequencing technologies. They will also analyze immune cell
subpopulations. The goal is to identify biomarkers to better define target
patient populations for future therapies. In addition, through computational
modeling approaches, the project aims to identify key molecular drivers of SLE
and LN kidney flares, and thereby to discover potential novel drug targets as
the basis for innovative therapies.

Under the terms of the agreement, EMD Serono and Pfizer, as sponsoring
members, will receive real-time access to all data and analysis. In addition,
both companies will have the ability to send a research scientist to the Broad
Institute to foster exchange of technology expertise in the area of
computational and experimental genomic profiling.

"We are thrilled to align with EMD Serono and Pfizer on an innovative project
to stratify SLE patients and identify candidate immune pathways underlying
lupus nephritis," said Prof. Nir Hacohen, Associate Professor at Massachusetts
General Hospital and Harvard Medical School, and Senior Associate Member at
the Broad Institute. "Technical advances now make it possible for us to
sequence RNA in very small numbers of cells, enabling us to be more
comprehensive in our analysis of cell types and states in Lupus patients. We
will collect millions of unbiased measurements from lupus patients over many
time points along with key clinical variables. We will use this dataset to
infer active biological pathways in these patients and develop novel dynamic
models of Lupus pathogenesis."

"The research group of Prof. Nir Hacohen from the Broad Institute is a pioneer
in the field of systems immunology and has developed a unique strategy to
dissect Lupus and Lupus Nephritis," said Harsukh Parmar, Head of the
Translational Innovation Platform Immunology & Neurodegenerative Diseases at
EMD Serono. "Combined with the Broad Institute's technical know-how, we see
this collaboration aiming for a significant contribution to potential future
innovative treatments of Lupus and Lupus Nephritis. This is in line with our
concept to integrate genomic profiling and system biology approaches
throughout our preclinical and clinical programs."

"We are pleased to collaborate with EMD Serono and the Broad Institute on
research designed to enhance our understanding of the molecular and cellular
underpinnings of Lupus, a debilitating disease that has long been a mystery to
the scientific community," said Johan Lund, Senior Vice President and Chief
Scientific Officer of Immunoscience at Pfizer. "This collaboration builds on
Pfizer's patient-centric and precision medicine-based approach to autoimmune
disease research, applying cutting edge technologies and a wealth of patient
level data with a goal of advancing our understanding of disease in order to
develop innovative therapies."

About EMD Serono, Inc.

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is a
specialized biopharmaceutical company dedicated to developing therapies with
groundbreaking potential. The company has strong market positions in
neurology, endocrinology and in reproductive health. In addition, EMD Serono
has an enduring commitment to solve the unsolvable, with state-of-the-art
science dedicated to developing new therapies in our core focus areas of
neurology, oncology, immuno-oncology and immunology. With a long-standing
history of industry expertise and a dedication to shape the future of
healthcare, the company's US footprint continues to grow, with approximately
1,000 employees around the country and fully integrated commercial, clinical
and research operations in the company's home state of Massachusetts.

For more information, please visit www.emdserono.com

About Merck KGaA, Darmstadt, Germany

Merck KGaA of Darmstadt, Germany, is a leading company for innovative and
top-quality high-tech products in the pharmaceutical and chemical sectors. Its
subsidiaries in Canada and the United States operate under the umbrella brand
EMD. Around 38,000 employees work in 66 countries to improve the quality of
life for patients, to further the success of customers and to help meet global
challenges. The company generated total revenues of €11.1 billion in 2013 with
its four divisions: Biopharmaceuticals, Consumer Health, Performance Materials
and Life Science Tools. Merck KGaA of Darmstadt, Germany is the world's oldest
pharmaceutical and chemical company – since 1668, the name has stood for
innovation, business success and responsible entrepreneurship. Holding an
approximately 70 percent interest, the founding family remains the majority
owner of the company to this day.

Worldwide there are two separate companies that bear the name "Merck," the
original Merck KGaA from Darmstadt, Germany, the oldest pharmaceutical and
chemical company in the world, and the pharmaceutical company Merck & Co. in
the United States. The rights to the name and trademark MERCK in North America
(USA and Canada) lie with Merck & Co., the former U.S. subsidiary of Merck,
whereas Merck KGaA operates in North America under the umbrella brand EMD. In
the rest of the world, Merck KGaA owns the rights to the Merck name and
trademark. This press release was distributed by Merck KGaA, Darmstadt,
Germany.

Logo - http://photos.prnewswire.com/prnh/20121220/SF32295LOGO-b

SOURCE EMD Serono, Inc.

Website: http://www.emdserono.com
Contact: Lisa Buffington, Phone: 781-681-2340
 
Press spacebar to pause and continue. Press esc to stop.